Kaveri Pohlman
Stock Analyst at Clear Street
(0.59)
# 4,063
Out of 5,048 analysts
27
Total ratings
26.92%
Success rate
-18.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $8.06 | +259.80% | 1 | Oct 22, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $41 → $60 | $29.35 | +104.43% | 2 | Oct 21, 2025 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $8.23 | +33.66% | 1 | Oct 1, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $26.18 | +75.71% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $17.60 | +81.82% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.58 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $28.71 | +63.71% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $7.81 | +284.12% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $13.94 | +172.60% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $5.17 | -3.29% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $27.37 | +126.53% | 1 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.81 | +109.97% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $38.06 | -29.06% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $20.35 | +243.98% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.99 | +503.02% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $3.93 | +103.56% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $4.03 | +122,182.88% | 2 | Feb 9, 2022 |
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $8.06
Upside: +259.80%
RAPT Therapeutics
Oct 21, 2025
Maintains: Buy
Price Target: $41 → $60
Current: $29.35
Upside: +104.43%
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $8.23
Upside: +33.66%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $26.18
Upside: +75.71%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $17.60
Upside: +81.82%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $28.71
Upside: +63.71%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $7.81
Upside: +284.12%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $13.94
Upside: +172.60%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $5.17
Upside: -3.29%
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $27.37
Upside: +126.53%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $3.81
Upside: +109.97%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $38.06
Upside: -29.06%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $20.35
Upside: +243.98%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $1.99
Upside: +503.02%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $3.93
Upside: +103.56%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $4.03
Upside: +122,182.88%